The final patient has been enrolled in a phase 1/2 study of Elate Ocular topical fibrinogen-depleted human platelet lysate biologic for the treatment of dry eye secondary to graft-versus-host disease, Cambium Medical Technologies announced in a press release.
The randomized, multicenter, double-masked, placebo-controlled parallel study enrolled 66 patients at nine centers. There are two study biologic cohorts and a placebo cohort.
“Cambium remains on track for Elate Ocular to be the first standardized, cGMP processed, allogeneic, enriched platelet-rich-plasma lysate serum drop approved
Uncategorized